Insider · CIK 0002043558
Jayson Rieger
Files at VRCA (Verrica Pharmaceuticals Inc.). First filing Nov 25, 2025, latest Nov 25, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VRCA: Verrica Pharmaceuticals Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 74Notable | Verrica Pharmaceuticals Inc. | $400k 94,311 shares | +107% | +56% from low-60% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Common Stock | +94,311 | $4.24 | $400k | 182,593 | Nov 25, 2025 |
| Nov 25, 2025 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Series C Warrant (right to buy)derivative | +23,577 | - | - | 23,577 | Nov 25, 2025 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Common Stock | +280,898 | - | - | 832,826 | Nov 26, 2024 |
| Nov 26, 2024 | VRCA Verrica Pharmaceuticals Inc. | GGift Common Stock | +50,000 | $0.00 | $0 | 882,826 | Nov 26, 2024 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Series A Warrants (right to buy)derivative | +140,449 | - | - | 140,449 | Nov 26, 2024 |
| Nov 22, 2024 | VRCA Verrica Pharmaceuticals Inc. | POpen-market purchase Series B Warrants (right to buy)derivative | +140,449 | - | - | 140,449 | Nov 26, 2024 |
| Nov 6, 2024 | VRCA Verrica Pharmaceuticals Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Nov 6, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.